Lianhua Technology: The company currently provides customers with high-end intermediate products of chlorfenapyr by the CDMO business model, and sells products only to this customer.

Lianhua Technology releases announcement on abnormal fluctuations in stock trading. The company currently provides customers with chlorfenapyr intermediate as a high-end intermediate under the CDMO business model, and the product is only sold to this customer. The pricing model for the product is cost plus markup, and as of now, the company has not received any notice from this customer regarding an increase in demand for the product. Therefore, the impact of these matters on the overall company is limited. In addition to the aforementioned matters, the company has not found any undisclosed significant information in recent public media reports that may or may have had a significant impact on the company's stock trading price. The company's recent production and operation conditions are normal, and there have been no significant changes in the company's business operations or internal and external operating environment.